Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| |
rdfs:comment
| - Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. (en)
|
foaf:name
| - Molecular Partners AG (en)
|
foaf:homepage
| |
name
| - Molecular Partners AG (en)
|
foaf:depiction
| |
dct:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
assets
| |
founded
| |
homepage
| |
hq location city
| - Schlieren, Zürich, Switzerland (en)
|
industry
| |
key people
| - Andreas Emmenegger, Chief Financial Officer (en)
- Dr. Michael Stumpp, Chief Operating Officer (en)
- Dr. Nicolas Leupin, Chief Medical Officer (en)
- Dr. Patrick Amstutz, Chief Executive Officer (en)
- William M. Burns, Chairman of the Board (en)
|
logo
| - Molecular_Partners_Logo.jpg (en)
|
num employees
| |
traded as
| |
type
| |
has abstract
| - Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. (en)
|
gold:hypernym
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
assets ($)
| |
founding year
| |
number of employees
| |
industry
| |
key person
| |